Navigation Links
St. Jude projects 90 percent cure rate for ALL

patient to treatment," Pui said. "That information helps us to determine how intensive the rest of the therapy should be. Our goal is the complete eradication of leukemic cells with the least toxicity to the children."

The continued improvement in diagnosis and treatment made possible by MRD, pharmacogenomics and new drug therapies has shifted the focus in ALL therapy toward reduction of both the immediate and long-term side effects of treatment. For example, a St. Jude team lead by Evans demonstrated that patients who lack the enzyme TPMT are more sensitive to thiopurine chemotherapy drugs and are more likely to suffer damage to the body's blood-producing cells. Evans subsequently discovered the genetic cause and developed a gene-based test that permits clinicians to identify children who should be treated with lower doses of this class of drugs while still receiving full therapeutic benefit. The overall improvements have led to more skilled use of cancer drugs, stem cell transplantation and treatment of ALL that invades the central nervous system, according to Pui.

"We are now testing the feasibility of omitting irradiation for all patients and reserving this treatment for only those children who suffer a relapse," he noted. "Irradiation of the brain can cause second cancers, hormonal disturbances and disruption of intellectual development as the child grows. So our omission of the use of irradiation should further reduce acute and long-term toxic side effects and improve outcome."

Coupled with the successes of the recent past, future treatment improvements promise to continually improve the survival rate of ALL, Evans said. For example, new drugs directed against the proteins made by genes linked to ALL will add to the options for treating this disease.

"Multiple breakthroughs at St. Jude and elsewhere have transformed ALL from a virtual death sentence into a disease that children can increasingly be expected to survive with minima
'"/>

Source:St. Jude Children's Research Hospital


Page: 1 2 3 4 5

Related biology news :

1. Disease diagnosis, biodefense among UH chemical research projects
2. Hunger in America rises by 43 percent over last five years
3. Method slashes quantum dot costs by 80 percent
4. Hepatitis B accounts for 40 percent of missing Asian women
5. Vaccine provides 100 percent protection against avian flu virus in animal study
6. Oceans are 70 percent shark free
7. BiovaxID?yields 89 percent survival in patients with aggressive non-Hodgkins
8. Biofuels can replace about 30 percent of fuel needs with significant research and policy effort
9. Psychotropic drug prescriptions for teens surge 250 percent over 7 year period
10. Just the expectation of a mirthful laughter experience boosts endorphins 27 percent, HGH 87 percent
11. Septum keeps neurons in synch, can reduce epileptic seizures by 90 percent
Post Your Comments:
*Name:
*Comment:
*Email:
TAG: Jude projects percent cure rate for ALL

(Date:11/21/2014)... , November 18, 2014 According ... Market by Systems (Video, RFID, Access Control, Intrusion Detection, ... Hotels, Banks, Government), Component Service Geography - Global Forecasts ... Market is projected to be around $25 Billion in ... 2020, growing at a CAGR of 8.69%. ...
(Date:11/21/2014)... -- C-Labs LLC, a leading provider of remote and ... announced the appointment of John Traynor to ... advisor to the firm, Mr. Traynor will now oversee ... out of the C-Labs office in Redmond, ... , Chief Executive Officer. Photo - ...
(Date:11/18/2014)... , Nov. 17, 2014   ... EMC collaborate to develop The Partners Data Lake, ... The Partners Data Lake will allow researcher and ... diagnostics, treatment and the lives of patients ... and clinical activities across the Partners system, breaking ...
Breaking Biology News(10 mins):Industrial Security Systems Market Worth $38 Billion by 2020 2Industrial Security Systems Market Worth $38 Billion by 2020 3C-Labs Names Former Microsoft and Bsquare Executive as Chief Operating Officer 2Partners HealthCare and EMC Unite to Solve Health Care's Toughest Challenges Using Big Data 2Partners HealthCare and EMC Unite to Solve Health Care's Toughest Challenges Using Big Data 3Partners HealthCare and EMC Unite to Solve Health Care's Toughest Challenges Using Big Data 4Partners HealthCare and EMC Unite to Solve Health Care's Toughest Challenges Using Big Data 5
... 2012Aspera, Inc., creators of next-generation software technologies that ... BGI, the world,s largest genomics research institute, today ... to integrate and deploy the Aspera Connect Server ... "EasyGenomicsTM", BGI,s latest cloud-based Software as a Service ...
... British Heart Foundation (BHF), has tested a new imaging method ... of having a heart attack (1). Scientists from ... in collaboration with the University of Cambridge are the first ... to image the disease processes directly in the coronary arteries ...
... anti-depressants appear to be doing patients more harm than good, ... of the medications on the entire body., "We need to ... drugs," says Paul Andrews, an evolutionary biologist at McMaster University ... online journal Frontiers in Psychology ., "It,s important ...
Cached Biology News:BGI and Aspera collaborate on high-speed data exchange to advance genome research 2Scientists develop new technique that could improve heart attack prediction 2Evidence shows that anti-depressants likely do more harm than good, researchers find 2
(Date:12/22/2014)... The Center for Professional Innovation ... training across the life sciences industry, has partnered with ... to provide the organization's members with discounted classroom courses, ... the more than 350 sessions across 80 course titles. ... when registering for a public course at ...
(Date:12/22/2014)... , Dec. 22, 2014 /PRNewswire/ - RepliCel Life ... regenerative medicine company focused on the development of autologous ... out of the University of Calgary in conjunction with ... Carolina, which further validates the company,s ongoing clinical research ... effects of pattern baldness. The paper entitled ...
(Date:12/22/2014)... Dec. 22, 2014 GenomeDx Biosciences today announced ... Cancer Classifier, a genomic test for prostate cancer, was ... men managed by radical prostatectomy without adjuvant therapy. Although ... relatively uncommon, using tumor genomics to identify these men ... is an important advance. The study has been ...
(Date:12/22/2014)... 22, 2014 The American ... of original research, reviews and editorials addressing developments ... practice, today published a provocative article exploring the ... progression and potential treatment of prostate cancer. ... and proposes the possibility that there could be ...
Breaking Biology Technology:CfPIE Announces Partnership with the Society for Clinical Data Management 2CfPIE Announces Partnership with the Society for Clinical Data Management 3Newly Released Peer-Reviewed Publication Further Validates RepliCel's Use of Dermal Sheath Cup Cells to Treat Pattern Baldness 2Newly Released Peer-Reviewed Publication Further Validates RepliCel's Use of Dermal Sheath Cup Cells to Treat Pattern Baldness 3Newly Released Peer-Reviewed Publication Further Validates RepliCel's Use of Dermal Sheath Cup Cells to Treat Pattern Baldness 4Newly Released Peer-Reviewed Publication Further Validates RepliCel's Use of Dermal Sheath Cup Cells to Treat Pattern Baldness 5Study Published in European Urology Shows that the Decipher Prostate Cancer Classifier is Predictive of Rapid Metastasis in High-Risk Men who have had Prostate Surgery 2Study Published in European Urology Shows that the Decipher Prostate Cancer Classifier is Predictive of Rapid Metastasis in High-Risk Men who have had Prostate Surgery 3Prostate Cancer Experts Dissect the Role of Follicle-stimulating Hormone in the Development, Progression and Potential Treatment of Prostate Cancer 2Prostate Cancer Experts Dissect the Role of Follicle-stimulating Hormone in the Development, Progression and Potential Treatment of Prostate Cancer 3Prostate Cancer Experts Dissect the Role of Follicle-stimulating Hormone in the Development, Progression and Potential Treatment of Prostate Cancer 4
... QUEBEC CITY, June 3, 2011 Asmacure ... of nicotinic receptor agonists for the treatment of asthma ... has been appointed as chief executive officer.  With a ... the company as it progresses its lead compound, a ...
... /PRNewswire-Asia-FirstCall/ -- China Cord Blood Corporation (NYSE: CO ... results for the fourth quarter and full year of fiscal ... in the US.   The Company will hold ... 13, 2011 to discuss its financial performance and give a ...
... Pharmaceuticals, Inc. (Nasdaq: ANTH ), today announced ... common stock in an underwritten public offering.  The Company expects ... to an additional 15% of the shares of common stock ...  Citi and Leerink Swann LLC are acting as joint book-running ...
Cached Biology Technology:Asmacure Ltee Appoints Pharmaceutical and Biotechnology Industry Veteran Martin Driscoll as CEO 2Asmacure Ltee Appoints Pharmaceutical and Biotechnology Industry Veteran Martin Driscoll as CEO 3China Cord Blood Corporation to Report Fourth Quarter and Full Year Fiscal 2011 Financial Results 2Anthera Pharmaceuticals Announces Proposed Public Offering of Common Stock 2Anthera Pharmaceuticals Announces Proposed Public Offering of Common Stock 3
...
...
...
... in the submicron range are part of ... and control of particle size is important ... can reliably detect the component populations in ... Particle Size Analyzer uses Photon Correlation Spectroscopy ...
Biology Products: